Lets get this over with, Its the last paragraph I edited.
We need updates on progress on all fronts.
Our recently filed Form 10-K and our Form 10-Q we filed yesterday with the SEC set forth all of the information about our progress that is publicly available. If there are material developments we believe should be disclosed, we will issue a press release. We are an Research and Development (“R&D”) company with projects involving cancer, ascites, diabetes and cannabinoids where we are trying to develop therapies for different indications. In any R&D enterprise, there are periods of high productivity and periods of lower overall productivity. This is because in the second type of R&D period the work being done is more difficult for various reasons and therefore it simply takes longer to complete. Things do not occur with regularity in R&D – it is not like paving a road where one can accurately predict when the entire job will be finished.
Is there still research being done on your behalf at The University of Northern Colorado involving cannabinoids and brain cancer?
Yes.
Are there any new results on the diabetes testing? Does this program still exist?
The program still very much exists. There are no results of our R&D to report at the present time.
Ascites?
This program still exists as well. Where things currently stand is described in our last 10-K.
I recommend to you that you appoint some shareholders to the board of directors that are not involved in daily operations of the company.
While we appreciate your recommendation, we have filled the Board with individuals who we feel will serve the Company’s best interests. We do not have plans to increase the size of the Board at the current time. An increase in your compensation should be performance based. Compensation of management is performance based. Management’s compensation is determined by our Compensation Committee and approved by the Board. For more information about the process, please review the 10-Ks we have filed with the SEC. The lack of updates does not support this. We respectfully disagree. We recognize that we have not published any information about developments in the company during August and thru today. However, there are several reasons for this: (i) we have been fully engaged with the preparation of our annual report on Form 10-K and working with our audit firm to timely file the 10-K; (ii) the same applies to the 10-Q we filed yesterday; (iii) we have been waiting on Austrianova and others to complete work over which we have no control; and (iv) we usually go dark during the months of August and early September because many shareholders and investors are taking vacations during this time. We often see a sell off of our stock during the summer months and then a pickup in shareholder activity after Labor Day.
The company told us the IND is "just about done". Please explain in more detail the status of OUR IND?
You are not alone in inquiring about the timeline for the filing of the IND for our clinical trial in pancreatic cancer. This is very difficult to pin down with certainty because most the work that remains to be done to complete the IND is now in the hands of Austrianova and our FDA regulatory consulting firm. We are informed and believe that they are working as diligently as possible, but PharmaCyte has no direct control over what they do and how quickly they do it. We have only final control of the accuracy and completeness of the work they perform for us. The latter are important factors because, when the IND is submitted to the FDA, PharmaCyte wants it to be as good as it possibly can be given the current FDA regulations. Please be assured that everyone at the company is working as diligently as possible to get the IND submitted and then the clinical trial underway. We are as anxious as you are to see these things happen.
PMCB is being vetted heavily by its shareholders at the moment and this will continue.
We have been advised of the numerous posts of Fred Flintstone on Investors Hub and the road he is encouraging other shareholders to take. But we also have been contacted by numerous shareholders that have a very different impression about PharmaCyte and the criticisms Mr. Flinstone levels at its management. More contact is not just appreciated but required. Please respond. Now that what we described above is behind us, we plan to begin to update shareholders as material events unfold. Look for a press release as early as next week. I myself, along with other shareholders will being knocking at your Laguna Hills door if these issues are not addressed. You are more than welcome to visit us in Laguna Hills. However, given how much we travel, we suggest making an appointment to be sure the person(s) you want to see are in the office.
News 
Market Data 
Discover 
AI
